However, in two Phase 2 clinical studies (CTRI/2021/09/036257 & CTRI/2021/08/035993) that we conducted during August– September 2021, when the infection rate was much lower, BBV154 induced 4 to 5-fold higher saliva IgA titers compared with baseline in seronegative subjects (see Supplementary Table 4). Here, CD79A is linked to infection.